June 2023: European Academy of Allergy and Clinical Immunology Annual Congress
Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Adult Subjects Followed for 3 Months
May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop
Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-acting preventative therapy in patients with hereditary angioedema (HAE) Types I or II
May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop
Mechanistic Modeling and Simulations Predict Long-Term HAE Attack Prevention with STAR-0215
February 2023: AAAAI Annual Meeting
Structure of STAR-0215 Bound to Active Plasma Kallikrein Reveals a Novel Mechanism of Enzyme Inhibition
February 2023: AAAAI Annual Meeting
Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema, in Healthy Adult Subjects Followed for at Least 3 Months
November 2022: ACAAI Annual Scientific Meeting
Modeling and Simulation Predicts Robust HAE Attack Suppression with Every 3 Month Dosing of STAR-0215
July 2022: EAACI Annual Congress
STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys
July 2022: EAACI Annual Congress
STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE
April 2022: Fc Receptor and IgG Targeted Therapies Conference
Development of STAR-0215: PKPD Model of STAR-0215, an Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE
February 2022: AAAAI Annual Meeting
STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE
